Thousands of men with prostate cancer could benefit from a drug developed to combat ovarian cancer.
Olaparib, which was designed to fight cancers caused by inherited mutations, stopped tumour growth in a third of advanced prostate cancer patients.
The study, from the Institute of Cancer Research in London, is the first time that a genetically targeted drug has worked against prostate cancer.
Dr Iain Frame, director of research at Prostate Cancer UK, said: “Sometimes we find answers to research questions from unexpected sources.”
Olaparib was licensed last year for women with ovarian cancer and inherited BRCA mutations but is not yet approved for NHS patients by the National Institute for Health and Care Excellence or the Cancer Drugs Fund.
Chairs: C.H. Bangma, NL – J. Hugosson, SE Co Chair: L. Klotz, CAN Honorary Chair: L.J. Denis, BE Host Chair: R. Valdagni, IT Scientific Coordinators: P. Carroll, US – M.J. Roobol, NL
Active surveillance is increasingly becoming an accepted initial strategy for the treatment of low risk prostate cancer.
Unless the over-diagnosis of prostate cancers is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role.
The challenge is to determine how and if new imaging technologies and genomic biomarkers can improve patient selection and monitoring. In addition, there is the challenge on how to incorporate the choice of available drugs into active surveillance programmes.
ESO’s third Inside Track Conference “Active surveillance for Low Risk Prostate Cancer” is organized in collaboration with EAU and endorsed by Europa Uomo. It aims at being an interactive educational activity in which attendees will enjoy presentations by internationally renowned researchers on active surveillance, who have helped develop and evaluate technologies that may change the selection and monitoring of low risk prostate cancer patients.
Furthermore, participatory workshops will allow discussions on a few selected hot topics with top experts in that field. Remarks and conclusions of the workshops will give important insights into active surveillance practices applied in various countries.
This multidisciplinary and multi-professional conference will provide highlights on the different aspects of a personalised approach to prostate cancer management in general and, in particular, on:
• Who to select for active surveillance and what can be the role of MRI and genetic markers
• Optimization of follow up protocols reducing unnecessary biopsies and when to switch to watchful waiting
• Quality of life and patient perspectives
On August 12 we launched a brand new website. Running on a professional platform and more flexible to update. This new version is also mobile ready, which means is easily readable on tablets and smartphones.
More content will be added in the coming days and weeks, we hope you enjoy it.
Please feel free to use the contact form for any remarks and/or suggestions.
We are delighted to announce that the European Prostate Awareness Day (EPAD) 2015 will take place in the European Parliament in Brussels on 16 September 2015, kindly hosted by Mr P. De Backer MEP. The event will be chaired by Mr De Backer MEP, Prof. C. Chapple, Secretary General of the European Association of Urology and Mr K. Mastris, Chairman of Europa Uomo. EPAD 2015 aims to raise awareness, understanding and knowledge of the management of prostate diseases in general and prostate cancer in particular, and their significant impact on the European male population.
The event brings together key policy makers, scientific experts, European associations working in the urological field and representatives of European patient groups with an interest in prostate disease. During this afternoon session several experts will elaborate what the impact is of living with benign prostatic enlargement and prostate cancer and how we can improve care and empower patients.
We hope you will be able to join the discussions! The invitation with the detailed agenda will follow.
For any questions or applications, please contact Anja Vancauwenbergh, Secretariat Europa Uomo, tel. +32 3 338 91 51, fax. +32 3 338 91 52, e-mail: email@example.com
Football’s loss was definitely urology’s gain when Per-Anders Abrahamsson gave up his aspirations to be a professional soccer player sand took up medicine. Per-Anders has been a collosus of urology. He stands tall, he walks even taller and he talks the talk.
The European School of Oncology is pleased to announce the 2nd edition of “ESO Prostate Cancer Observatory inoovation and care in the next 12 months”, which will be held during teh EAU15 Congress on March 20 in Madrid, chaired by Prof. H. van Poppel and Prof. R. Valdagni.
Discussion about the topic mentioned in the heading has been raised in a LinkedIn group called Beat Prostate Cancer. Simon Crompton, English health journalist, has also handled the same topic widely and to his credit including patient stories in an article in May-June issue of Cancer World.
In the beginning of his article he summarizes: “Every patient wants to be cured. But a culture that defines success as “cure” condemns many patients and doctors to failure. Should the cancer community be looking to broaden the concept of success to better reflect how well care plans deliver the best possible outcome tailored to each patient’s personal priorities?”
Are the ones seeing the topic from patient’s perspective left out from open discussion? Or is it seen as a medical question that only is a professional matter for doctors and researchers to speculate on? It is natural that treatments are thoroughly discussed between patient and doctor when planning and deciding about the treatment. The question however is whether the “silent thought” of cure being the only successful outcome in cancer care living in community gives justice to the patient. Or does it even compare to general treatment knowledge of today? From a broader perspective I think it is relevant to question if the persistent thought of relating cancer and death to each other is based on this same definition of successful outcome – cure.